3 Mid-Cap Stocks with Open QuestionsMid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Winners And Losers Of Q4: Waters Corporation (NYSE:WAT) Vs The Rest Of The Research Tools & Consumables StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
3 Cash-Producing Stocks Walking a Fine LineA company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
3 Reasons to Sell WAT and 1 Stock to Buy InsteadSince September 2025, Waters Corporation has been in a holding pattern, posting a small return of 3.8% while floating around $311.11. Is there a buying oppor...
3 Reasons to Avoid WAT and 1 Stock to Buy InsteadWaters Corporation trades at $306.57 per share and has stayed right on track with the overall market, gaining 5.7% over the last six months. At the same time...
1 S&P 500 Stock on Our Buy List and 2 We IgnoreThe S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Danaher Corporation (DHR): Navigating the Bioprocessing Thaw and the Masimo PivotAs of February 17, 2026, Danaher Corporation (
NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
WAT Q4 Deep Dive: Acquisition Integrates BD Biosciences, Margin Pressures Offset Revenue GrowthScientific instruments company Waters Corporation (
NYSE:WAT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $932.4 million. The company expects next quarter’s revenue to be around $1.20 billion, coming in 64.5% above analysts’ estimates. Its non-GAAP profit of $4.53 per share was in line with analysts’ consensus estimates.
The Measurement Giant Reimagined: A Deep Dive into Waters Corporation (WAT) in 2026As of February 10, 2026, Waters Corporation (
NYSE: WAT) stands at the most significant crossroads in its nearly 70-year history. Long regarded as the gold standard in liquid chromatography and mass spectrometry, the Milford, Massachusetts-based company has recently transitioned from a specialized toolmaker into a multi-disciplinary life sciences juggernaut. With the closing of its massive [...]
Waters Corporation (NYSE:WAT) Reports Q4 CY2025 In Line With ExpectationsScientific instruments company Waters Corporation (
NYSE:WAT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $932.4 million. The company expects next quarter’s revenue to be around $1.20 billion, coming in 64.5% above analysts’ estimates. Its non-GAAP profit of $4.53 per share was in line with analysts’ consensus estimates.
Pure-Play Pivot: Decoding Becton Dickinson’s (BDX) Q1 Results and the $17.5B Waters CombinationToday, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (
NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (
NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
1 Profitable Stock on Our Buy List and 2 We AvoidWhile profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
3 Mid-Cap Stocks We Steer Clear OfMany investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&AAs 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
3 Cash-Producing Stocks Walking a Fine LineGenerating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
